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Abstract: Hydatid disease caused by tapeworm is an increasing public health and   socioeconomic 
concern. In order to enhance the therapeutic efficacy of praziquantel (PZQ) against tapeworm, 
PZQ-loaded hydrogenated castor oil solid lipid nanoparticle (PZQ-HCO-SLN) suspension was 
prepared by a hot homogenization and ultrasonication method. The stability of the suspension at 
4°C and room temperature was evaluated by the physicochemical characteristics of the nanopar-
ticles and in-vitro release pattern of the suspension. Pharmacokinetics was studied after subcuta-
neous administration of the suspension in dogs. The therapeutic effect of the novel formulation 
was evaluated in dogs naturally infected with Echinococcus granulosus. The results showed that 
the drug recovery of the suspension was 97.59% ± 7.56%.   Nanoparticle diameter, polydisper-
sivity index, and zeta potential were 263.00 ± 11.15 nm, 0.34 ± 0.06, and −11.57 ± 1.12 mV , 
respectively and showed no significant changes after 4 months of storage at both 4°C and room 
temperature. The stored suspensions displayed similar in-vitro release patterns as that of the 
newly prepared one. SLNs increased the bioavailability of PZQ 5.67-fold and extended the 
mean residence time of the drug from 56.71 to 280.38 hours. Single subcutaneous administra-
tion of PZQ-HCO-SLN suspension obtained enhanced therapeutic efficacy against tapeworm 
in infected dogs. At the dose of 5 mg/kg, the stool-ova reduction and negative conversion rates 
and tapeworm removal rate of the suspension were 100%, while the native PZQ were 91.55%, 
87.5%, and 66.7%. When the dose reduced to 0.5 mg/kg, the native drug showed no effect, but 
the suspension still got the same therapeutic efficacy as that of the 5 mg/kg native PZQ. These 
results demonstrate that the PZQ-HCO-SLN suspension is a promising formulation to enhance 
the therapeutic efficacy of PZQ.
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Introduction
Hydatid disease is a cause of substantial morbidity and mortality in most of the world, 
including parts of Europe, North America, South America, Asia, and Africa.1–3 It is a 
chronic cyst-forming parasitic helminthic disease of human beings as well as domestic 
and wild ungulates.4 This disease can result in a 10% decrease in whole of life perfor-
mance for infected animals (reduction in quality of meat, production of fiber,   production 
of milk, and the number of surviving offspring).5 Dogs are the definitive hosts that 
harbor the adult stage of the parasite, thus prophylaxis and therapy of tapeworm infec-
tion in dogs is the decisive step avoiding transmission of this disease to humans and 
livestock.4,6 Many programs have been implemented to remove the parasite in different 
countries/areas, such as continuous dosing of praziquantel (PZQ ) tablets or baits to 
dogs once or twice a week for years,7,8 but control of the transmission of tapeworm International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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infection is very difficult. For example, it took New Zealand 
and Tasmania more than 30 years to eliminate the parasite 
infection following dog-targeted chemotherapy control.8 The 
program in Uruguay had little effect on livestock or human 
cystic echinococcosis rates over the first 20 years of the 
campaign.9 Epidemiologically, human cystic   echinococcosis 
occurs predominantly in poor agricultural and pastoral 
communities.7 The poverty often relates to the failure of the 
community to adopt control measures. Therefore, achieving 
a high level of disease transmission control, reducing the cost 
of a control program, and increasing compliance from dog 
owners should be considered.
PZQ is one of the first-line anthelmintic drugs for treating 
tapeworm infections and has become the cornerstone for 
hydatid control campaigns worldwide.10 It has potent ces-
tocidal activity against Taenia taeniaeformis, Echinococcus 
granulosus, Mesocestoides vogae, M. corti, Dipylidium cani-
num, and Hymenolepis diminuta in animals and humans.11,12 
PZQ is highly effective on mature and immature tapeworm 
species tested in mice, rats, cats, dogs, and sheep.11 Although 
PZQ is a very effective anthelmintic, it is practically insoluble 
in water and has poor bioavailability because of extensive 
hepatic first-pass metabolism and rapid clearance from the 
bloodstream with a terminal elimination half-life (t½(el)) of 
1–3 hours.13,14 Repeated administration of high dose PZQ over 
a long time for therapy of cestode infection is required. For 
example, the common usage of PZQ is up to 75 mg/kg per 
day for 15–20 days preoperatively for hydatid disease caused 
by Echinococcus spp.15 The dose of PZQ is 50 mg/kg/day 
for 15 days for the cysticercus stage of Taeniasolium, espe-
cially in its localization in the brain (neurocysticercosis).16 
Frequent administration is not only time-wasting, but also 
costly. Moreover, repeated medication is too complex to 
efficiently achieve satisfactory mass control. The high daily 
dose might produce a slight transient disturbance in general 
wellbeing, such as tiredness, dizziness, nausea, and hangover 
feeling.17
To overcome these shortcomings, new strategies of 
delivery are necessary. Some researchers have developed 
the long-term sustained-release implantable PZQ-containing 
bar and PZQ-loaded sustained-release PCL implant.18,19 
Liposomal formulations have also been prepared to improve 
the bioavailability, systemic circulation time, and cestocidal 
activity of PZQ.20,21
Previous studies demonstrate that solid lipid nanopar-
ticles (SLNs) significantly prolong the systemic circula-
tion time and increased the bioavailability of PZQ.22,23 The 
improved bioavailability and systemic circulation time 
of PZQ could enhance its therapeutic efficacy and reduce 
dose and   administration frequency. SLNs are usually pro-
duced as either aqueous dispersions (suspensions) or dry 
  powders. Suspensions are preferred with regard to the ease 
of handling (no reconstitution necessary) and for cost rea-
sons (eg, cost of freeze drying).24 It has been reported that 
aqueous dispersions of SLNs were basically stable under 
the optimization of the storage conditions for up to 3 years; 
however, some systems show particle growth followed by 
gelation.24,25 Alternatively, the liquid can be converted into 
a dry product by spray drying or lyophilization to avoid 
occurring instabilities.24
In this work, a PZQ-loaded hydrogenated castor oil 
(HCO)-SLN (PZQ-HCO-SLN) suspension was prepared. The 
stability of the suspension was evaluated by physicochemical 
characteristics of the nanoparticles and in-vitro release prop-
erty of the suspension. The pharmacokinetics and therapeutic 
efficacy of the suspension were studied in dogs.
Materials and methods
Materials
HCO was purchased from Tongliao Tonghua Castor   Chemical 
Co, Ltd (Inner Mongolia, China). PZQ reference standard 
was bought from China Institute of Veterinary Drug Control 
(Beijing, China). Native PZQ was obtained from Wuhan 
Kanglong Century Technology Development Co, Ltd 
(Wuhan, China). Poly vinyl alcohol (PVA) was purchased 
from Sigma (St Louis, MO). Methyl alcohol used for high 
performance liquid chromatography (HPLC) was of liquid 
chromatography grade, available from Tedia Company, Inc 
(Fairfield, OH). The water was prepared with a Millipore 
(Bedford, MA) Milli-Q® system.
Preparation of PZQ-hcO-sLN 
suspension
The PZQ-HCO-SLN suspension was prepared by the hot 
homogenization and ultrasonication method as described 
previously.23 Briefly, HCO (17 g) and PZQ (3 g) were added 
in a 250 mL beaker and put in a boiling water bath. After the 
lipid–drug mixture became a clear melting solution, 130 mL 
of boiling 1% PVA solution was poured into the lipid phase 
under magnetic stirring, and sonicated for 20 minutes with a 
VCX 750 Vibra-Cell™ (Sonics and Materials, Inc,   Newtown, 
CT), using the 13 mm microprobe with amplitude 35%, to 
form a nanoemulsion. The hot nanoemulsion was cooled 
down to obtain a nanoparticle suspension. The   control nano-
particle suspension was prepared in the same way without 
adding PZQ.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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scanning electron microscopy (seM)  
of sLNs
The morphology of nanoparticles was studied by SEM 
(SE S-3400N; Hitachi, Tokyo, Japan). Briefly, 2 µL of the 
nanoparticle suspension was placed on a glass surface. After 
oven-drying, the samples were coated with gold using an 
ion sputter for 3 minutes and examined at an accelerating 
voltage of 20 kV .
Determination of drug recovery
To determine the drug recovery from the suspension, 0.2 mL 
suspension was added into a 15 mL tube containing 9.8 mL 
methyl alcohol. The tube was heated on a boiling water 
bath for 10 minutes and then centrifuged at 10,000 rpm 
  (Centrifuge 5810 R; Eppendorf, Germany) for 25 minutes. 
The PZQ in the supernatant was measured by HPLC using a 
UV Detector at wavelength 215 nm (Shimadzu   Corporation, 
Kyoto, Japan). The control nanoparticle suspension with-
out PZQ was treated similarly and used as blank for the 
  measurements. The assay was repeated three times using 
different samples from independent preparations. Drug 
recovery is defined as follows:
Drug recovery =   (Weight of PZQ in suspension 
/Weight of PZQ added) × 100.  (1)
Determination of diameter, polydispersity 
index, and zeta potential of SLNs
The diameter, polydispersity index, and zeta potential of 
nanoparticles was measured by photon correlation spec-
troscopy (PCS Zetasizer Nano ZS90; Malvern Instruments, 
Worcestershire, UK). The nanoparticle suspension was 
diluted by 60 times for the determination of particle size and 
polydispersity index, and diluted by 360 times for zeta poten-
tial determination to get optimum kilo counts per   second of 
20–400 for measurements.
In-vitro release study
PZQ-HCO-SLN suspension (0.2 mL) was added in 1.8 mL 
0.9% (w/v) sodium chloride (NaCl) solution (donor   solution) 
in a dialysis bag (molecular weight: 8000–14,400) and 
dialyzed against 45 mL 0.9% (w/v) NaCl solution (receiver 
solution) in a 50 mL tube at 37°C under magnetic stirring 
at 100 rpm. At fixed times, the receiver solution was taken 
for PZQ quantitation by HPLC, and the dialysis bag was 
transferred to another 50 mL tube containing 45 mL fresh 
solution. The control nanoparticle formulation without PZQ 
was treated similarly and used as blank for the measurements. 
The experiments were carried out in triplicate.
stability evaluation
Stability of the nanoparticle suspension was evaluated after 
the samples were stored at 4°C and room temperature for 
4 months. The nanoparticle diameter, polydispersity index, 
and zeta potential, and the in-vitro release patterns, were used 
for the evaluation of the physical stability of the nanoparticle 
suspension. The assay was repeated three times using differ-
ent samples from independent preparations.
Pharmacokinetic study
Xinjiang indigenous dogs (15–27 kg) were fed at the 
  Veterinary Research Institute of Animal Science Academy of 
Xinjiang Uygur Autonomous Region, China. All experimental 
protocols concerning the handling of dogs were in accordance 
with the requirements of the experimental animal ethics/Ethics 
Committee at Animal Science Academy of Xinjiang Uygur 
Autonomous Region. The animals were housed at room tem-
perature with free access to a standard diet and water. Before 
initiation of the experiment, ten healthy dogs were randomly 
divided into two groups, with five animals in each group. 
A single dose (5 mg/kg) of PZQ-HCO-SLN suspension or 
native PZQ suspended in 0.9% sterile NaCl at drug concentra-
tion of 2% (w/v) was then subcutaneously administered into 
the cervical area of the dogs. At different time points post 
injection, blood samples were taken from the vena cervicalis, 
and the drug levels in the plasma were assayed.
hPLc assay
PZQ concentrations in plasma were measured by HPLC. Sample 
extracts were prepared by mixing 1 mL plasma with 6 mL 
mixture of methyl tert-butyl ether and dichlormethane (2:1 v/v). 
The mixtures were vortexed for 3 minutes to allow complete 
mixing, followed by centrifugation at 14,000 rpm (Sigma 1–14; 
Sartorius, Germany) for 25 minutes. The supernatant was then 
incubated in a fan-assisted oven (65°C, 30 minutes) and was dis-
solved in 300 µL mobile phase. A 100 µL aliquot was taken for 
HPLC analysis. Chromatographic conditions were as   follows: 
reverse phase C18 column, VP-ODS, 250 mm × 4.6 mm 
  (Shimadzu Corporation, Kyoto, Japan); mobile phase, 
  acetonitrile/Milli-Q water (60/40, v/v); flow rate, 1.0 mL/min; 
column temperature, 20°C; and UV detector wavelength, 
215 nm. The plasma concentration of PZQ was found to be 
linear over the range 5–2000 ng/mL. The correlation coefficient 
was 0.9999. The quantification limit of the method for PZQ in 
plasma was 5 ng/mL. The extraction recovery for the plasma International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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PZQ from three concentrations (10, 100, and 500 ng/mL) was 
89.1% ± 0.8%, 94.2% ± 3.6%, and 91.1% ± 1.2%, respectively. 
The relative standard deviations of accuracy and precision for 
three different plasma concentrations of PZQ (10, 100, and 
500 ng/mL) were 4.5%, 0.6%, and 3.4%, respectively, for 
inter-day analysis, and 1.9%, 3.8%, and 1.3%, respectively, 
for intra-day analysis.
Pharmacokinetic analysis
The plasma concentrations versus time data were analyzed 
based on noncompartmental pharmacokinetics using PK 
Solutions 2.0 (Ashland, OH) software. The plasma drug 
concentrations over time data were used to calculate the area 
under the concentration–time curve (AUC0–∞) and the mean 
residence time (MRT) of the PZQ-HCO-SLN suspension 
and native PZQ.
Therapeutic trials
The therapeutic trials of PZQ-HCO-SLN suspension were 
performed in Xinjiang indigenous adult dogs naturally 
infected with E. granulosus. Fecal samples were taken from 
each dog pretreatment to confirm the E.   granulosus infection 
by epidemiology survey, egg microscopy, and coproantigen 
enzyme-linked immunosorbent assay determination.26,27 Forty 
infected dogs were randomized into five treatment groups, 
with eight animals per group. Two drug doses (0.5 mg/kg and 
5 mg/kg) in the form of either PZQ-HCO-SLN suspension or 
native PZQ suspended in 0.9% sterile sodium chloride at drug 
concentration of 2% (w/v) were subcutaneously administered 
into four groups of dogs. One untreated group was used as 
control. Fecal samples were taken daily from each animal 
for 1 week post-treatment. Samples were analyzed using 
the saturated sucrose flotation technique,28 and the number 
of eggs per gram of feces was calculated. At the end of the 
experiment, three dogs from each treatment were sacrificed 
and their intestines were examined for the presence of tape-
worms.11 If no tapeworm was found, they were considered 
as removed by the drug. The efficacy of the treatment was 
determined as stool-ova reduction rate,29 stool-ova negative 
conversion rate,30 and tapeworm removal rate.11
 
Stool-ova reduction rate (%) = 
Epg before treatment - Epg a after treatment 
Epg before treatment
100  ×
 
(2)
 
Stool-ova negative conversion rate (%) 
=
Number of negative   animal for tapeworm egg in a treatment group
Total number   of animal in the treatment group
100
  
× (3)
 
Tapeworm removal rate (%) = 
Number of animal without E.gran nulosus in a treatment group
Total number of animal in the   treatment group
100 ×   (4)
where EPG is eggs per gram.
statistical methods
The data on nanoparticle diameter, polydispersity index, zeta 
potential, and pharmacokinetic parameters of PZQ-HCO-
SLN suspension and native PZQ suspension were analyzed 
using one-way analysis of variance. Significance was evalu-
ated at P-value of 0.05. Statistical analysis was performed 
using Microsoft Excel (2003).
Results
Physicochemical characteristics  
of the sLNs
The drug recovery from the nanoparticle suspension was 
97.59%. SEM studies showed that the nanoparticles were 
spherical with smooth surfaces and had no differences after 
4 months of storage at 4°C and room temperature (Figure 1). 
The diameter, polydispersivity index, and zeta potential of 
nanoparticles displayed no significant changes after 4 months 
of storage at 4°C and room temperature as compared with 
that of the fresh preparation (Table 1).
In-vitro release
The stored nanoparticle suspension displayed the same 
release pattern as that of the fresh preparation. In-vitro 
release curve of the SLN suspension exhibited a biphasic 
pattern with a fast release from 55.33% to 58.20% within 
the initial 12 hours, followed by a slow and sustained release 
(Figure 2). The amount of cumulated release over 48 hours 
was 56.79%–60.69%, and the daily release rate was lower 
than 0.5%. In contrast, the release rate of native PZQ sus-
pension was much faster. The cumulative release was up to 
91.03% by 12 hours. The release almost completed (96.00%) 
by 48 hours.
Pharmacokinetics
Plasma PZQ concentration–time curves are shown in 
Figure 3. The pharmacokinetic parameters are depicted 
in Table 2. After subcutaneous administration of native 
PZQ, the plasma drug concentration reached a peak 
level of 47.82 ng/mL at 1.45 hours, then decreased to the 
quantification limit (5 ng/mL) by 48 hours and was unde-
tectable by 72 hours. In the HCO-SLN suspension group, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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ABC
500 µm 500 µm 500 µm
Figure 1 scanning electron microscopy graphs of PZQ-hcO-sLN (65,000×): (A) Newly prepared sLNs, (B) sLNs stored at 4°c for 4 months; and (C) sLNs stored at 
room temperature for 4 months.
Abbreviations: PZQ-HCO-SLN, praziquantel-loaded hydrogenated castor oil solid lipid nanoparticle suspension; SLN, solid lipid nanoparticle.
Table 1 The physicochemical characteristics of PZQ-hcO-sLN 
(mean ± sD, n = 3)
Formulation MD, nm PDI ZP, mV
Newly prepared sLNs 263.00 ± 11.15 0.34 ± 0.06 −11.57 ± 1.12
sLNs stored at 4°c 256.00 ± 20.22 0.37 ± 0.05 −10.87 ± 0.71
sLNs stored at room  
temperature
260.67 ± 19.22 0.36 ± 0.09 −12.33 ± 0.81
Abbreviations: MD, mean diameter; PDI, polydispersity index; PZQ-hcO-sLN, 
praziquantel-loaded  hydrogenated  castor  oil  solid  lipid  nanoparticle  suspension; 
SD, standard deviation; SLN, solid lipid nanoparticle; ZP, zeta potential.
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Figure 2 In-vitro release of PZQ-hcO-sLN (mean ± sD, n = 3).
Abbreviations:  PZQ,  praziquantel;  PZQ-HCO-SLN,  praziquantel-loaded 
hydrogenated castor oil solid lipid nanoparticle suspension; sD, standard deviation; 
sLN, solid lipid nanoparticle.
PZQ reached a significantly higher peak concentration of 
113.70 ng/mL at 1.93 hours and then decreased to the same 
level as that of native drug by 8 hours. The plasma drug 
concentration in the SLN group was higher than that of the 
native drug group again after 24 hours and maintained over 
5 ng/mL for up to 264 hours. The plasma drug concentration 
was undetectable in the SLN group by 312 hours.
The pharmacokinetic analysis revealed that t½(el) and MRT 
of PZQ-HCO-SLN were significantly longer than those of 
native PZQ (Table 2). Moreover, the AUC0−∞ and maximal 
PZQ concentration (Cmax) of the PZQ-HCO-SLN suspension 
was 5.67- and 2.38-fold higher, respectively, than those 
obtained with the native PZQ (Table 2).
Therapeutic efficacy
The therapeutic efficacy in dogs naturally infected with 
E. granulosus is shown in Table 3. At PZQ dose of 5 mg/kg, 
no egg was detected from the stool of dogs in the SLN group, 
while the stool-ova reduction and negative conversion rates in 
the native PZQ group were 91.55% and 87.5%, respectively. 
When the drug dose reduced to 0.5 mg/kg, the stool-ova 
reduction and negative conversion rates in the SLN group 
were 96.76% and 87.5%, but they dropped dramatically to 
22.08% and 0% in the native PZQ group.
Intestine examination showed that the tapeworm was 
only present in the stool-ova-positive dogs, therefore the 
tapeworm removal rates with different treatment were the 
same as that of the stool-ova negative conversion rates in 
the sacrificed dogs.
Discussion
The physicochemical characteristics of the nanoparticle sus-
pension were similar to that of the freeze-dried PZQ-HCO-
SLN prepared in the authors’ previous study, and the drug 
recovery from the nanoparticle suspension was high. Due to 
the presence of unincorporated drug in the suspension, the 
initial release rate of the PZQ-HCO-SLN suspension within 
2 hours was faster than that of lyophilized PZQ-HCO-SLN, 
but the subsequent release was very similar to that of freeze 
dried nanoparticles.23 The results demonstrated that the 
PZQ-HCO-SLN suspension is an effective sustained-release 
formulation.
The nanoparticle diameter, polydispersivity index, 
zeta potential, and release pattern have always been used 
to evaluate the stability of nanoparticle suspensions.24,31 
The HCO-SLN suspension did not have agglomeration, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 3 Plasma PZQ concentration–time curves after a single dose of subcutaneous administration of PZQ-hcO-sLN and PZQ suspension (5 mg/kg) (mean ± sD, n = 5): 
(A) within 8 hours, (B) from 12 to 312 hours.
Abbreviations: PZQ, praziquantel; SLN, solid lipid nanoparticle.
Table  2  Pharmacokinetic  parameters  of  PZQ-hcO-sLN  and  PZQ  suspension  after  subcutaneous  administration  in  dog   
(mean ± sD, n = 5)
Formulation t½(ab), hours t½(d), hours t½(el), hours tmax, hours Cmax, ng/mL MRT, hours AUC0-∞, ng ⋅ h/mL
PZQ-sLN 0.31 ± 0.11 4.36 ± 1.81 189.62 ± 80.72a 1.93 ± 1.09 113.70 ± 37.27a 280.38 ± 116.41a 5898.17 ± 2048.73a
Native PZQ 0.97 ± 0.80 2.60 ± 0.79 34.53 ± 19.15 1.45 ± 1.07 47.82 ± 13.06 56.71 ± 23.41 1039.98 ± 149.19
Note: aStatistical significances compared with native drug are P , 0.05.
Abbreviations: AUc0−∞, area under the concentration–time curve from zero to infinity; Cmax, maximal PZQ concentration in plasma; MrT, mean residence time; 
PZQ, praziquantel; PZQ-HCO-SLN, praziquantel-loaded hydrogenated castor oil solid lipid nanoparticle suspension; SD, standard deviation; SLN, solid lipid nanoparticle; 
t½(ab), absorption half-life; t½(d), distribution half life; t½(el), elimination half-life; tmax, time to reach cmax.
and the physicochemical characteristics had no significant 
changes after being stored at both 4°C and room tempera-
ture for 4 months, indicating the SLN suspension had good 
stability.
Subcutaneous administration of PZQ is one of the effec-
tive routes of cestode infection in animals.11,32 A previous 
study demonstrates that subcutaneous administration of 
PZQ-SLN is superior to oral and intramuscular routes for 
enhanced drug bioavailability and systemic circulation 
time.23 Therefore, the subcutaneous route was selected for 
pharmacokinetic study in this present work.
The PZQ-HCO-SLN suspension significantly extended 
the systemic circulation time and enhanced the bioavail-
ability of PZQ. However, the Cmax of PZQ-HCO-SLN 
suspension was higher than that obtained with native PZQ, 
which is inconsistent with our previous study on lyophilized 
PZQ-HCO-SLN. This might be due to the free drug in 
the suspension, which could micronize or formulate pure 
drug nanoparticles in the preparation process, resulting 
in increased dissolution and swift absorption of the drug. 
In addition, the emulsifier could enhance the solubility of 
unentrapped drug, thus increasing the absorption rate of a 
drug at the injection site.33 Mass chemotherapy with PZQ 
can reduce the prevalence of tapeworm.34 However, the effect 
could only be sustained with continued regular use of PZQ 
baits. Once baiting ceases, animals become reinfected within 
a few months.34 The extended systemic circulation time of 
PZQ could decrease the dosage frequency, which is favorable 
to mass control of tapeworm infection.
E. granulosus prevalences are found in all continents 
and at least 100 countries.35 There are 22 provinces, autono-
mous regions, and municipalities in China reported with 
cystic echinococcosis, which is regarded as one of the major 
public health problems.36 In Xinjiang, the prevalence of 
cystic echinococcosis in humans, sheep, cattle, and dogs 
was 0.07–28.40, 6.10–100.00, 2.00–88.00, and 0–51.80, 
  respectively.36 In this study, dogs infected with E. granulosus 
were chosen to evaluate the anthelmintic activity of the SLN 
suspension using two PZQ doses. The high dose of 5 mg/kg 
was based on the clinic dosage.11 Subcutaneous administration 
of 5 mg/kg is effective in eliminating tapeworm from dogs.37,38 
Considering the enhancement of pharmacological activity of 
PZQ by SLNs, a low dose of 0.5 mg/kg was also used to assess 
the therapeutic efficacy of the SLN   suspension. At both doses, 
the stool-ova reduction and negative conversion rates and 
tapeworm removal rate indicate that the SLN   suspension could International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Table 3 stool-ova reduction and negative conversion, and tapeworm removal rates post-treatment
Treatment Dosage,  
mg/kg
Stool-ova reduction  
rate, %
Stool-ova negative  
conversion rate, %
Tapeworm  
removal rate, %
PZQ-sLN 5     100 ± 0 100 (8/8) 100 (3/3)
PZQ-sLN 0.5 96.76 ± 9.16 87.5 (7/8) 66.7 (2/3)
Native PZQ 5 91.55 ± 23.88 87.5 (7/8) 66.7 (2/3)
Native PZQ 0.5 22.08 ± 29.42 0 (0/8) 0 (0/3)
Untreatment 0 13.89 ± 21.36 0 (0/8) 0 (0/3)
Abbreviations: PZQ, praziquantel; SLN, solid lipid nanoparticle.
significantly enhance the therapeutic efficacy and decrease the 
clinic dosage of PZQ. Since the cestocidal activity of PZQ 
is concentration- and time-dependent,11,21,28 exposure of the 
tapeworm to higher drug concentrations and/or longer time 
is essential for adequate treatment of parasite infection. In 
addition, the high drug concentration and long drug action 
time have a synergistic effect to enhance the cestocidal activity 
of PZQ.21 Based on the pharmacokinetics of the suspension 
and cestocidal mechanisms of PZQ, the enhanced cestocidal 
activity against other cestodes might be anticipated, but further 
studies need to be done to confirm its broad efficiency to treat 
tapeworm infections in most mammals.
Conclusion
The PZQ-HCO-SLN suspension has good stability stored at 
4°C and room temperature. The SLN suspension significantly 
enhances the pharmacological activity and therapeutic efficacy 
of PZQ. The PZQ-HCO-SLN suspension would be a prom-
ising formulation for prophylaxis and therapy of tapeworm 
infection. The nanoparticle suspension would be an efficient 
alternative formulation for tapeworm transmission control.
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